Dolastatin 15, a mollusk linear peptide, and Celecoxib, a selective cyclooxygenase-2 inhibitor, prevent preneoplastic colonic lesions and induce apoptosis through inhibition of the regulatory transcription factor NF-κB and an inflammatory protein, iNOS

European Journal of Cancer Prevention

Volumn 21, Issue 6, 2012, Pages 511-522

  Piplani, Honit ^a   Vaish, Vivek ^a   Sanyal, Sankar Nath ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Apoptosis; Colonic neoplasms; Inducible nitric oxide synthase; Molecular docking

Indexed keywords

1,2 DIMETHYLHYDRAZINE; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DOLASTATIN 15; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER PREVENTION; COLON CANCER; COLON CARCINOGENESIS; COLON MUCOSA; COMPUTER MODEL; CONTROLLED STUDY; ENZYME BINDING; ENZYME INHIBITION; ENZYME SYNTHESIS; HISTOPATHOLOGY; INFLAMMATION; INTESTINE CELL; MALE; MOLECULAR DOCKING; NONHUMAN; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; TREATMENT DURATION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DEPSIPEPTIDES; FLUORESCENT ANTIBODY TECHNIQUE; INTESTINAL MUCOSA; MALE; MOLECULAR DOCKING SIMULATION; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PRECANCEROUS CONDITIONS; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES;

EID: 84866980922     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e328351c69d     Document Type: Article

References (42)

1. Badtian I, Colebunders R (1999). Treatment and prevention of multidrug-resistant tuberculosis. Drugs 58:633-661.
2. Bai R, Pettit GR, Homel E (1990). Binding of Dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem 265:17141-17149.
3. Bai R, Pettit GR, Hamwel E (1992). Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol 43:2637-2645.
4. Bernhard B, Knethen A, Sandau K (1999). Nitric oxide (NO): an effector of apoptosis. Cell Death Differ 6:969-975.
5. Bertagnolli M, Eagle C, Zauber A, Redston M, Solomon S, Kim K, et al. (2006). Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355:873-884.
6. Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
7. Chaplin DJ, Pettit GR, Parkins CS, Hill SA (1996). Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br J Cancer 74:86-88.
8. Clara S, Giuseppe N, Jacopo M, Emilio C (1997). Nitric oxide effects on cell growth: GMP-dependent stimulation of the AP-1 transcription complex and cyclic GMP-independent slowing of cell cycling. Br J Pharmacol 122: 687-697.
9. Cryer B, Dubois A (1998). The advent of highly selective inhibitors of cyclooxygenase - a review. Prostaglandins Other Lipid Mediat 56:341-361.
10. Daisy P, Sasikala R, Ambika A (2009). Analysis of binding properties of phosphoinositide 3-kinase through in silico molecular docking. J Proteomics Bioinform 2:274-284.
11. De Arruda M, Coccharo CA, Nelson CM (1995). LU103793 (NSC D-669356): a synthetic peptide that interacts with microtubules and inhibits mitosis. Cancer Res 55:3085-3092.
12. Greten F, Karin M (2004). The IKK/NF-kB activation pathway - a target for prevention and treatment of cancer. Cancer Lett 206:193-199.
13. Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G (2001). COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 14:2742-2744.
14. Herszenyi L, Farinati F, Miheller P, Tulassay Z (2008). Chemoprevention of colorectal cancer: feasibility in everyday practice? Eur J Cancer Prev 6: 502-514.
15. Kaur J, Sanyal SN (2010a). PI3-kinase/Wnt association mediates COX-2/PGE2 pathway to inhibit apoptosis in early stages of colon carcinogenesis: chemoprevention by diclofenac. Tumor Biol 31:623-631.
16. Kaur J, Sanyal SN (2010b). Modulation of inflammatory changes in early stages of colon cancer through activation of PPARg by diclofenac. Eur J Cancer Prev 5:319-327.
17. Kaur J, Sanyal SN (2010c). Oxidative stress and stress-signaling in chemoprevention of early colon cancer by diclofenac. Am J Biomed Sci 2:63-78.
18. Kaur J, Sanyal SN (2011). Intracellular pH and calcium signaling as molecular targets of diclofenac-induced apoptosis against colon cancer. Eur J Cancer Prev 20:263-276.
19. Kijjoa A, Sawangwong P (2004). Drugs and cosmetics from the sea. Mar Drugs 2:73-82.
20. Lee SJ, Lim KT (2008). A 116-kDa phytoglycoprotein inhibits aberrant crypt foci formation through modulation of manganese superoxide dismutase, inducible nitric oxide synthase, cyclooxygenase-2, nuclear factor-kappa B, activator protein-1, and proliferating cell nuclear antigen in 1,2-dimethylhydrazine/ dextran sodium sulfate-treated ICR mice. Eur J Cancer Prev 17:479-488.
21. Marnett LJ, DuBois R (2002). COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol 42:55-80.
22. Marx J (2001). Anti-inflammatories inhibit cancer growth - but how? Science 291:581-582.
23. McMurray R, Hardy K (2002). Cox-2 inhibitors: today and tomorrow. Am J Med Sci 323:181-189.
24. Mouille B, Robert V, Blachier F (2004). Adaptive increase of ornithine production and decrease of ammonia metabolism in rat colonocytes and hyperproteic diet ingestion. Am J Physiol Gastrointest Liver Physiol 287:344-351.
25. Parks DR, Bryan VM, Oi VT, Herzenberg LA (1979). Antigen-specific identification and cloning of hybridomas with a fluorescence-activated cell sorter. Proc Natl Acad Sci USA 76:1962-1966.
26. Piccagli L, Fabbri E, Borgatti M, Bezzerri V, Mancini I, Nicolis E, et al. (2008). Docking of molecules identified in bioactive medicinal plants extracts into the p50 NF-kappaB transcription factor: correlation with inhibition of NF-kappaB/ DNA interactions and inhibitory effects on IL-8 gene expression. BMC Struct Biol 8:38.
27. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, et al. (1995). Expression of cyclooxygenase-1 and 2 in human colorectal cancer. Cancer Res 55:3785-3789.
28. Sato M, Sagawa M, Nakazato T, Ikeda Y, Kizaki M (2007). A natural peptide, dolastatin 15, induces G2/M cell cycle arrest and apoptosis of human multiple myeloma cells. Int J Oncol 30:1453-1459.
29. Sengupta A, Ghosh S, Das R, Bhattacharjee S, Bhattacharya S (2006). Chemopreventive potential of diallylsulfide, lycopene and theaflavin during chemically induced colon carcinogenesis in rat colon through modulation of cyclooxygenase-2 and inducible nitric oxide synthase pathways. Eur J Cancer Prev 4:301-305.
30. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey R, Marrow J, et al. (1997). Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 99:2254-2259.
31. Simmons TL, Andrianasolo E, Mcphail K, Flatt P, Gerwick WH (2005). Marine natural products as anticancer drugs. Mol Cancer Ther 4:333-342.
32. Slack J (1999). The biology and treatment of acute progranulocytic leukemia. Curr Opin Oncol 11:9-13.
33. Smith ML, Hawcroft G, Hull MA (2000). The effect of non-steroidal antiinflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eur J Cancer 36:664-674.
34. Stockbrügger RW (1999). Nonsteroidal anti-inflammatory drugs (NSAIDs) in the prevention of colorectal cancer. Eur J Cancer Prev 8:S27.
35. Tanwar L, Vaish V, Sanyal SN (2009). Chemoprevention of 1, 2-dimethylhydrazine-induced colon carcinogenesis by a non-steroidal anti-inflammatory drug, Etoricoxib, in rats: inhibition of nuclear factor-kB. Asian Pacific J Cancer Prev 10:1141-1146.
36. Tanwar L, Piplani H, Sanyal SN (2010a). Anti-proliferative and apoptotic effects of etoricoxib, a selective COX-2 inhibitor, on 1,2-dimethylhydrazine dihydrochloride-induced colon carcinogenesis. Asian Pac J Cancer Prev 11:1329-1333.
37. Tanwar L, Vaish V, Sanyal SN (2010b). Chemopreventive role of etoricoxib (MK-0663) in experimental colon cancer: induction of mitochondrial proapoptotic factors. Eur J Cancer Prev 19:280-287.
38. Vaish V, Tanwar L, Sanyal SN (2010). The role of NF-kB and PPARg in experimentally induced colorectal cancer and chemoprevention by cyclooxygenase-2 inhibitors. Tumour Biol 31:427-436.
39. Vandoros G, Konstantinopoulos P, Bonikou G, Kominea A, Papachristou G, Karamouzis M, et al. (2006). PPAR-gamma is expressed and NF-KB pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas. J Cancer Res Clin Oncol 132:76-84.
40. Yamada K, Okjia M, Kigoshi H, Suenaga K (2000). Cytotoxic substances from Opisthobranch molluscs. In: Fusetani N, editor. Drugs from the sea. Basel: Karger AG; pp. 59-73.
41. Yamamoto Y, Gaynor R (2001). Therapeutic potential of inhibition of the NF-kB pathway in the treatment of inflammation and cancer. J Clin Invest 107: 135-142.
42. Young J, Kyung C, Hyun C, Seong H, Young K, Kwang P, et al. (2001). Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kB activation. Mutat Res 480:243-268.